ada guidelines ozempic initiation semaglutide 2024 Stop treating Type 2 Diabetes with 'the next glycemic drug.' Modern and KDIGO clinical demand a shift: manage comorbidities first, glycemic targets second. If your patient has established ASCVD, heart 2025 Update ✨ GLP-1 and

Referral to hepatology should be considered for persistent unexplained LFT elevation 6 months, high FIB-4 score, abnormal elastography/imaging, or signs of clinical decompensation

The CNS is especially susceptible to oxidative damage (Cordeiro, 2014)

I had one questionable elevated glucose reading that I cross-checked with a commercial-grade glucometer, which was within 10 points, so I assume the CGM component is accurate

The CJC-1295/ipamorelin combination amplifies nighttime GH pulsatility for recovery and metabolic support

Next Steps With Everlywell Spotlight on Featured content 86% of cancers aren't caught by recommended screenings